NCT02381886Active, not recruitingPhase 1
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 166 (actual)
- First submitted
- 2 Mar 2015
- Start date
- 6 Mar 2015
- Primary completion date
- 7 Dec 2016
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Myelodysplastic syndromes, Liver and biliary tract cancer, Glioblastoma, Acute myeloid leukemia
- NCT number
- NCT02381886
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 166
- From 6 Mar 2015 to the primary completion date, 7 Dec 2016
- 16 sites in 8 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received prior treatment with a mutant-specific IDH1 inhibitor (with the exception of glioma patients)
Other illness
- Medical conditions that would prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures such as the presence of other clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological disease.
Other
- Acute Promyelocytic Leukemia
- Women who are pregnant or lactating
- Other protocol-defined Inclusion/Exclusion may apply
Who the study is looking for
- Documented IDH1R132-mutant tumors
- ECOG performance status ≤ 2
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (16)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
| - Coordinator of this site? Confirm its status | Parkville | Australia | Unknown status |
| - Coordinator of this site? Confirm its status | Leuven | Belgium | Unknown status |
| - Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Cologne | Germany | Unknown status |
| - Coordinator of this site? Confirm its status | Heidelberg | Germany | Unknown status |
| - Coordinator of this site? Confirm its status | Jena | Germany | Unknown status |
| - Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
| ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55 Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
| - Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Dana Farber Cancer Institute SC (1) Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Uni Of TX MD Anderson Cancer Cntr Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| Columbia University Medical Center- New York Presbyterian Onc Dept. Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Columbia University Medical Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.